Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 clinical trials
Also written PF-08634404 and SSGJ-707.
Its developmentBy Pfizer and 3SBio, step by step15 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
15 studies that test it; most in 2026 (7)
| Year | Studies |
|---|---|
| 2024 | 4 |
| 2025 | 4 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
Pfizer (10) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (4) · Shenyang Sunshine Pharmaceutical Co., LTD. (1)
Often tested with
Tested in the same studies.
Oxaliplatin (1) · Capecitabine (1) · Leucovorin (1) · Fluorouracil (1) · Pemetrexed (1) · Paclitaxel (1) · Immune checkpoint inhibitors (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404.
- Oct 2027Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.Phase 1/2 · Pfizer
- Nov 2027Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPhase 1/2 · Pfizer
Studies
Open first, then newest update. How each study uses Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone or With Chemotherapy, in Adult Participants With Extensive-Stage Small Cell Lung CancerRecruitingPhase 2/3PfizerNCT07226999Written as PF-08634404How we know
- Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial CancerRecruitingPhase 3PfizerNCT07578649Written as PF-08634404How we know
- Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal CancerRecruitingPhase 2/3PfizerNCT07392892Written as PF-08634404How we know
- Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerRecruitingPhase 2PfizerNCT07476287Written as PF-08634404How we know
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Written as PF-08634404How we know
- Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial CancerRecruitingPhase 1/2PfizerNCT07421700Written as PF-08634404How we know
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingPhase 1/2PfizerNCT07227012Written as PF-08634404How we know
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 3PfizerNCT07222566Written as PF-08634404How we know
- Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal CancerRecruitingPhase 3PfizerNCT07222800Written as PF-08634404How we know
- Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLCRecruitingPhase 2PfizerNCT07489066Written as PF-08634404How we know
- A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer PatientsRecruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06522828Written as SSGJ-707How we know
- A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer PatientsRecruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06493760Written as SSGJ-707How we know
- A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC PatientsRecruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06412471Written as SSGJ-707How we know
- A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC PatientsRecruitingPhase 2Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.NCT06361927Written as SSGJ-707How we know
- SSGJ-707 in Advanced Non-Small Cell Lung CancerTerminatedPhase 3Shenyang Sunshine Pharmaceutical Co., LTD.NCT06980272Written as SSGJ-707How we know
Given beside what is tested · 1 — Anti-PD-1/Anti-VEGF Bispecific Antibody PF-08634404 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 21, 2026.
Started recruiting1
Stopped1
- SSGJ-707 in Advanced Non-Small Cell Lung CancerTerminatedNov 18, 2026NCT06980272